The estimated Net Worth of Jeremy M Levin is at least $7.06 million dollars as of 18 March 2024. Jeremy Levin owns over 18,248 units of Ovid Therapeutics Inc stock worth over $4,050,721 and over the last 14 years he sold OVID stock worth over $0. In addition, he makes $3,008,980 as Chairman of the Board et Chief Executive Officer at Ovid Therapeutics Inc.
Sign up
Jeremy Levin OVID stock SEC Form 4 insiders trading
Jeremy has made over 10 trades of the Ovid Therapeutics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 18,248 units of OVID stock worth $50,364 on 18 March 2024.
The largest trade he's ever made was buying 75,000 units of Ovid Therapeutics Inc stock on 22 February 2019 worth over $150,000. On average, Jeremy trades about 11,355 units every 259 days since 2010. As of 18 March 2024 he still owns at least 3,616,715 units of Ovid Therapeutics Inc stock.
You can see the complete history of Jeremy Levin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeremy Levin biography
Dr. Jeremy Max Levin serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Levin served as President and Chief Executive Officer, of Teva Pharmaceutical Industries Ltd., or Teva, a publicly held pharmaceutical company, from May 2012 to October 2013. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, finally serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the Executive Committee at Bristol-Myers Squibb Company. Prior to that, Dr. Levin served as Global Head of Strategic Alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG, from 2002 to 2007. Dr. Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company, H. Lundbeck A/S, a publicly traded pharmaceutical company, and ZappRx, Inc., a private e-health company. Dr. Levin is also a serving member on the board of the Biotechnology Innovation Organization. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as Chairman and Chief Executive Officer of Cadus Pharmaceuticals Corporation, a drug development company. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his BA in Zoology, MA in Cell Biology and Doctorate in Chromatin Structure, all from University of Oxford, and his MB and BChir from the University of Cambridge. Levin’s extensive experience in the global biotechnology and pharmaceutical industry qualifies him to serve on our Board.
What is the salary of Jeremy Levin?
As the Chairman of the Board et Chief Executive Officer of Ovid Therapeutics Inc, the total compensation of Jeremy Levin at Ovid Therapeutics Inc is $3,008,980. There are no executives at Ovid Therapeutics Inc getting paid more.
How old is Jeremy Levin?
Jeremy Levin is 67, he's been the Chairman of the Board et Chief Executive Officer of Ovid Therapeutics Inc since 2015. There are 3 older and 12 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
What's Jeremy Levin's mailing address?
Jeremy's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK, NY, 10001.
Insiders trading at Ovid Therapeutics Inc
Over the last 9 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan et Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
What does Ovid Therapeutics Inc do?
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
What does Ovid Therapeutics Inc's logo look like?
Complete history of Jeremy Levin stock trades at Ovid Therapeutics Inc et Bristol-Myers Squibb Co
Ovid Therapeutics Inc executives and stock owners
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeremy Levin,
Chairman of the Board, Chief Executive Officer -
Amit Rakhit,
President, Chief Medical Officer -
Dirk Haasner,
Senior Vice President - Global Regulatory Affairs -
Timothy Daly,
Executive Vice President - Finance, Corporate Controller, Treasurer -
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Pres, CEO & Chairman -
Thomas Michael Perone J.D., M.B.A.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jeffrey A. Rona,
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer -
Bart Friedman,
Lead Independent Director -
Douglas Williams,
Independent Director -
Karen Bernstein,
Independent Director -
Barbara Duncan,
Independent Director -
Jason Tardio,
Chief Commercial Officer -
Thomas Perone,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Luke Rosen,
Sr. VP of Accelerated Devel. & Community Engagement -
Dr. Claude Nicaise,
Head of R&D -
Dr. Dirk Haasner,
Sr. VP of Global Manufacturing & CMC QA -
Suzanne K. Wakamoto SHRM-SCP, SPHR,
Sr. VP of HR -
Lora Pike,
Sr. Director of Investor Relations & PR -
Jason Tardio M.B.A.,
Chief Commercial Officer & COO -
Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP,
Founder & Member of Scientific Advisory Board -
Matthew During,
Director -
Yaron Werber,
CBO, CFO, Sec. and Treas. -
Pharmaceutical Co Ltdmillen...,
-
Ana Ward,
SVP and General Counsel -
Robert Michael Poole,
Director -
Pharmaceutical Co Ltd Taked...,
-
Kevin Joseph Fitzgerald,
Director -
Margaret A. Alexander,
President and COO -
Jeffrey A Rona,
CBFO